WO2001068700A3 - Regulation of human substance p-like g protein-coupled receptor - Google Patents

Regulation of human substance p-like g protein-coupled receptor Download PDF

Info

Publication number
WO2001068700A3
WO2001068700A3 PCT/EP2001/002861 EP0102861W WO0168700A3 WO 2001068700 A3 WO2001068700 A3 WO 2001068700A3 EP 0102861 W EP0102861 W EP 0102861W WO 0168700 A3 WO0168700 A3 WO 0168700A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
disease
protein
reagents
Prior art date
Application number
PCT/EP2001/002861
Other languages
French (fr)
Other versions
WO2001068700A2 (en
Inventor
Shyam Ramakrishnan
Original Assignee
Bayer Ag
Shyam Ramakrishnan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Shyam Ramakrishnan filed Critical Bayer Ag
Priority to AU2001242459A priority Critical patent/AU2001242459A1/en
Priority to EP01915335A priority patent/EP1294758A2/en
Publication of WO2001068700A2 publication Critical patent/WO2001068700A2/en
Publication of WO2001068700A3 publication Critical patent/WO2001068700A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reagents which regulate human substance P G protein-coupled receptor (SP-GPCR) protein and reagents which bind to human SP-GPCR gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, urinary incontinence, inflammatory diseases (e.g., arthritis, psoriasis, asthma and inflammatory bowel disease), anxiety, depression or dysthymic disorders, cluster headache, colitis, psychosis, pain, allergies such as eczema and rhinitis, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina, migraine and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological disorders such as Alzheimer's disease, AIDS related dementia, diabetic neuropathy and multiple sclerosis, disorders related to immune enhancement or suppression such as systemic lupus erythematosus, and rheumatic diseases such as fibrositis.
PCT/EP2001/002861 2000-03-17 2001-03-14 Regulation of human substance p-like g protein-coupled receptor WO2001068700A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001242459A AU2001242459A1 (en) 2000-03-17 2001-03-14 Regulation of human substance p-like g protein-coupled receptor
EP01915335A EP1294758A2 (en) 2000-03-17 2001-03-14 Regulation of human substance p-like g protein-coupled receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18997200P 2000-03-17 2000-03-17
US60/189,972 2000-03-17

Publications (2)

Publication Number Publication Date
WO2001068700A2 WO2001068700A2 (en) 2001-09-20
WO2001068700A3 true WO2001068700A3 (en) 2002-03-21

Family

ID=22699530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/002861 WO2001068700A2 (en) 2000-03-17 2001-03-14 Regulation of human substance p-like g protein-coupled receptor

Country Status (3)

Country Link
EP (1) EP1294758A2 (en)
AU (1) AU2001242459A1 (en)
WO (1) WO2001068700A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1332157A2 (en) 2000-11-03 2003-08-06 The Regents of the University of California Prokineticin polypeptides, related compositions and methods
EP1437592A4 (en) * 2001-09-20 2007-10-10 Astellas Pharma Inc Novel screening method using prokineticin receptor
US20030203847A1 (en) * 2002-02-28 2003-10-30 Millennium Pharmaceuticals, Inc. Methods and compositions in treating pain and painful disorders using 9949, 14230, 760, 62553, 12216, 17719, 41897, 47174, 33408, 10002, 16209, 314, 636, 27410, 33260, 619, 15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 16314, 1613, 1675, 9569 or 13424 molecules

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046620A1 (en) * 1997-04-17 1998-10-22 Millennium Pharmaceuticals, Inc. A novel human g-protein coupled receptor
WO2000034334A1 (en) * 1998-12-10 2000-06-15 Synaptic Pharmaceutical Corporation DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF
WO2001016309A1 (en) * 1999-08-27 2001-03-08 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
WO2001036471A2 (en) * 1999-11-17 2001-05-25 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046620A1 (en) * 1997-04-17 1998-10-22 Millennium Pharmaceuticals, Inc. A novel human g-protein coupled receptor
WO2000034334A1 (en) * 1998-12-10 2000-06-15 Synaptic Pharmaceutical Corporation DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF
WO2001016309A1 (en) * 1999-08-27 2001-03-08 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
WO2001036471A2 (en) * 1999-11-17 2001-05-25 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 1 October 2000 (2000-10-01), XP002176970, retrieved from HOMO SAPIENS Database accession no. Q9NTT0 *
DATABASE WPI Section Ch Week 200123, Derwent World Patents Index; Class B04, AN 2001-226684, XP002176971 *

Also Published As

Publication number Publication date
AU2001242459A1 (en) 2001-09-24
EP1294758A2 (en) 2003-03-26
WO2001068700A2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
CN1178932C (en) Amide derivatives
Hogwood et al. Measurement and control of host cell proteins (HCPs) in CHO cell bioprocesses
CN1156452C (en) Heterocyclic urea and related compounds useful as anti-inflammatory agents
Ménard et al. Successful cognitive aging in rats: a role for mGluR5 glutamate receptors, homer 1 proteins and downstream signaling pathways
AU676489B2 (en) Quinuclidine derivative as substance P antagonist
CN1280259C (en) Aryl aniline beta-2 adrenergic receptor agonists
WO2007009083A3 (en) Compounds with activity at retinoic acid receptors
CN1378537A (en) Pyrimidine derivatives
WO2007036745A3 (en) Interleukin-13 antibody composition
CN1321151A (en) Chemical compounds
WO2001068700A3 (en) Regulation of human substance p-like g protein-coupled receptor
WO2001087929A3 (en) Regulation of human dopamine-like g protein-coupled receptor
CN88100650A (en) Anti-inflammatory agent
CN1735595A (en) Substituted alkyl amido piperidines
Takeiwa et al. Exportin‐5 mediates nuclear export of SRP RNA in vertebrates
Leino et al. Intranasal exposure to a damp building mould, Stachybotrys chartarum, induces lung inflammation in mice by satratoxin‐independent mechanisms
Rech et al. Recombinant proteins in plants
DE60226414D1 (en) HUMAN G-PROTEIN COUPLED RECIPE
Rababa'h et al. The Protective Role of L-carnitine on Psychosocial Stress-induced Changes in Gene Expression and Protein Levels of Matrix Metalloproteinases, Serum Corticosterone in a Rat Model
WO2001088127A3 (en) Regulation of human follicle stimulating hormone-like g protein-coupled receptor
Raymond et al. Production of IgGs with a human-like sialylation in CHO cells
KOTAKI et al. A tuning method for PID controller under consideration of changes in plant characteristics
Bv et al. Glial immune-related pathways as mediators of closed head TBI effects on behavior in Drosophila
Wines et al. Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
Verma et al. Allergenicity Assessment of Genetically-modified Tobacco Expressing Salt Tolerance cbl Gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001915335

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10220289

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001915335

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001915335

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP